Procalcitonin, C-reactive protein, and cell counts in the diagnosis of parapneumonic pleural effusions

Journal of Investigative Medicine

Volumn 58, Issue 8, 2010, Pages 971-976

  San José, M Esther ^a   Valdés, Luis ^a   Vizcaíno, Luis H ^a   Mora, Teresa ^a   Pose, Antonio ^a   Soneira, Esther ^a   Crecente, Carmen ^a   González Barcala, Francisco J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

C reactive protein; Leukocyte; Parapneumonic effusions; Pleural effusions; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PARAPNEUMONIC PLEURAL EFFUSION; PLEURA EFFUSION; PLEURA FLUID; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 78651494832     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181f88648     Document Type: Article

References (30)

1. Light RW. Textbook of Pleural Diseases. 2nd ed. London, UK, Hodder Arnold; 2008:341-366.
2. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007;45(11):1480-1486.
3. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J. 1997;10:1150-1156.
4. Deiros L, Baquero-Artigao F, García-Miguel MJ, et al. Derrame pleural paraneumónico: revisión de 11 años. An Pediatr (Barc). 2006;64(1):140-145.
5. Bueno M, Agúndez B, Jimeno S, et al. ¿Está aumentando la incidencia de derrames pleurales paraneumónicos? An Pediatr (Barc). 2008;68(2):92-98.
6. Porcel JM. Enfermedades de la Pleura. Lleida, Spain: Universitat de Lleida. 2002:47-63.
7. Ferguson AD, Prescott RJ, Selkon JB, et al. The clinical course and management of thoracic empyema. Q J Med. 1996;89:285-289.
8. Davies CW, Kearney SE, Gleeson FW, et al. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med. 1999;160:1682-1687.
9. Santotoribio JD, León-Justel A, Delgado-Pecellín C, et al. What are the biochemical parameters of pleural fluid that best identify parapneumonic effusions? Ann Clin Biochem. 2009;46(Pt 2):176-177.
10. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med. 1980;69(4):507-512.
11. Porcel JM, Vives M, Esquerda A, et al. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir Med. 2006;100:933-937.
12. Oberhoffer M, Karzai W, Meier-Hellmann A, et al. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999;27:1814-1818.
13. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003;21:939-943.
14. Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patient outcome team pneumonia severity index. Chest. 2005;128:2223-2229.
15. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
16. Gaïni S, Koldkjaer OG, Moller HJ, et al. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care. 2007;11: R76.
17. Charles PE, Ladoire S, Snauwaert A, et al. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis. 2008;8:163-173.
18. Pfäfflin A, Scheleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem. 2009;393(5):1473-1480.
19. Cakir E, Deniz O, Ozcan O, et al. Pleural fluid and serum procalcitonin as diagnostic tools in tuberculous pleurisy. Clin Biochem. 2005;38:234-238.
20. Lin MC, Chen YC, Wu JT, et al. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest. 2009;136(1):205-211.
21. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
22. Garcia-Pachon E, Llorca I. Diagnostic value of C-reactive protein in exudative pleural effusions. Eur J Intern Med. 2002;13:246-249.
23. Garcia-Pachon E, Soler MJ, Padilla-Navas I, et al. C-reactive protein in lymphocytic pleural effusions: a diagnostic aid in tuberculous pleuritis. Respiration. 2005;72:486-489.
24. Kiropoulos TS, Kostikas K, Oikonomisi S, et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Repir Med. 2007;101(5):910-918.
25. Daniil ZD, Zintzaras E, Kiropoulos T, et al. Discrimination of exudative pleural effusions based on multiple biological parameters. Eur Respir J. 2007;30:957-964.
26. Valdés L, San José E, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme and interferon gamma. Chest. 1993;103(2):458-465.
27. Alexandrakis MG, Coulocheri SA, Bouros D, et al. Significance of alpha-2-macroglobulin, alpha-1-acid glycoprotein, and C-reactive protein in pleural effusion differentiation. Respiration. 2000;67:30-35.
28. Castaño JL, Amores C. Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions. Eur J Med. 1992;1(4):201-207.
29. Light RW, Erozan YS, Ball WC. Cells in pleural fluid: their value in differential diagnosis. Arch Intern Med. 1973;132:854-860.
30. Porcel-Pérez JM, Vives Soto M, Esquerda Serrano A, et al. Cutoff values of biochemical test son pleural fluid: their usefulness in differential diagnosis of 1, 040 patients with pleural effusions. An Med Interna. 2004;21(3):113-117.